Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients
- PMID: 12465154
Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients
Abstract
Objective: To compare the risk of ovarian failure and the fertility of women treated with intravenous cyclophosphamide (IVCY) according to the underlying inflammatory disease.
Methods: Review of the data of 84 consecutive women: 56 with systemic lupus erythematosus (SLE), 28 with other diseases, mainly Wegener's granulomatosis and systemic vasculitides.
Results: The mean age at IVCY initiation was 29 +/- 10 years (range 13-53). The mean dosage was 0.9 +/- 0.14 g per pulse (range 0.5-1), and the mean number of pulses 13 +/- 6.5 (range 3-42). With a mean followup of 5.1 +/- 3.7 years, 23 women developed amenorrhea, with a mean duration of 4 +/- 3.6 months between IVCY initiation and amenorrhea. Amenorrhea was sustained in 19 women (13 with SLE and 6 with other diseases, NS). The mean age at ovarian failure onset was 40 +/- 7.6 years. The risk of ovarian failure correlated with the age at IVCY institution (p < 0.0001), and was independent of underlying inflammatory disease. Eighteen women (13 with SLE and 5 with other diseases) became pregnant during or after CY therapy, with a total of 22 pregnancies. The mean age at IVCY initiation, and the mean number of IVCY (maximum 40 pulses) before pregnancy were similar in women with SLE and those with other diseases. Six pregnancies occurred during IVCY therapy, which ended in induced abortion (n = 3), spontaneous abortion (n = 1), and normal pregnancy after IVCY withdrawal (n = 2) in women who wished to keep their pregnancy despite the risk of teratogenicity. Sixteen pregnancies occurred 2.9 +/- 2.1 years (range 1-9) after IVCY withdrawal. They ended in: 3 induced abortions indicated for severe morphological anomalies (n = 2) and for SLE relapse (n = 1), 3 spontaneous miscarriages, and 10 deliveries of healthy newborns.
Conclusion: The risk of ovarian failure depends essentially on the age at IVCY initiation. Pregnancy may occur during IVCY therapy, and an efficient contraception is mandatory. After IVCY withdrawal, pregnancy is possible with a favorable outcome in two-thirds of the cases.
Similar articles
-
Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.J Rheumatol. 2002 Oct;29(10):2129-35. J Rheumatol. 2002. PMID: 12375322 Clinical Trial.
-
Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.Arthritis Rheum. 1998 May;41(5):831-7. doi: 10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1. Arthritis Rheum. 1998. PMID: 9588734
-
[Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].Acta Reumatol Port. 2008 Jan-Mar;33(1):69-76. Acta Reumatol Port. 2008. PMID: 18344924 Portuguese.
-
[Ovulation induction therapy and systemic lupus erythematosus].Ann Med Interne (Paris). 2003 Feb;154(1):45-50. Ann Med Interne (Paris). 2003. PMID: 12746658 Review. French.
-
Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.Minerva Endocrinol. 2007 Mar;32(1):23-34. Minerva Endocrinol. 2007. PMID: 17353864 Review.
Cited by
-
Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case Series.Inflamm Intest Dis. 2018 Mar;2(3):139-146. doi: 10.1159/000481820. Epub 2017 Nov 22. Inflamm Intest Dis. 2018. PMID: 30018965 Free PMC article.
-
Possible novel biomarkers of organ involvement in systemic lupus erythematosus.Clin Rheumatol. 2014 Aug;33(8):1025-31. doi: 10.1007/s10067-014-2560-z. Epub 2014 Mar 6. Clin Rheumatol. 2014. PMID: 24599678 Review.
-
Anti-CD20 monoclonal antibodies: reviewing a revolution.Hum Vaccin Immunother. 2018;14(12):2820-2841. doi: 10.1080/21645515.2018.1508624. Epub 2018 Sep 6. Hum Vaccin Immunother. 2018. PMID: 30096012 Free PMC article.
-
Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation.Rheumatol Int. 2016 Nov;36(11):1563-1568. doi: 10.1007/s00296-016-3531-2. Epub 2016 Aug 13. Rheumatol Int. 2016. PMID: 27522225
-
Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding.Paediatr Drugs. 2018 Dec;20(6):511-521. doi: 10.1007/s40272-018-0312-2. Paediatr Drugs. 2018. PMID: 30175398 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous